Gabriele Baj was supported by a fellowship from Fondazione Kathleen Foreman Casali-Trieste, FRA-UniTS 2012 and Beneficentia Stiftung-Vaduz (Lichtenstein)
Injection-site redness or transient irritation (more common with cagrilintide)
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Glutathione + Berberine: Supporting Synergy for Late-Summer Vitality Imagine experiencing a body that can both respond well to environmental challenges and efficiently utilize nutrients for energy
Understanding how to mix peptides with bacteriostatic water properly is a foundational skill